alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2022244EN.01001601.xml

| 27.6.2022 | EN | Official Journal of the European Union | C 244/16 |
| --- | --- | --- | --- |

27.6.2022

EN

Official Journal of the European Union

C 244/16

---

Request for a preliminary ruling from the Tribunal Judicial da Comarca do Porto — Juízo Local Cível da Maia (Portugal) lodged on 15 March 2022 — WH, NX v TAP — Transportes Aéreos Portugueses, SGPS, SA

(Case C-202/22)

(2022/C 244/20)

Language of the case: Portuguese

Referring court

Tribunal Judicial da Comarca do Porto — Juízo Local Cível da Maia

Parties to the main proceedings

Applicants: WH, NX

Defendant: TAP — Transportes Aéreos Portugueses, SGPS, SA

Questions referred

| 1. | In the light of Articles 5(1)(c), 6(1), 7(1) and 8(1)(b) of Regulation No 261/2004, (1) must compensation be paid in the same way as it is for flight delays where transport to the final destination by bus, which is provided by an operating air carrier to passengers who missed a flight connection, is very late? |
| --- | --- |

1.

In the light of Articles 5(1)(c), 6(1), 7(1) and 8(1)(b) of Regulation No 261/2004, (1) must compensation be paid in the same way as it is for flight delays where transport to the final destination by bus, which is provided by an operating air carrier to passengers who missed a flight connection, is very late?

| 2. | In the light of recital 14 and Article 7(3) of Regulation No 261/2004, does the breakdown of that bus and the need to replace it on the journey to the final destination constitute an extraordinary circumstance which exempts the air carrier from the obligation to pay compensation to passengers where the bus arrives at the final destination much later than its scheduled or expected arrival time? |
| --- | --- |

2.

In the light of recital 14 and Article 7(3) of Regulation No 261/2004, does the breakdown of that bus and the need to replace it on the journey to the final destination constitute an extraordinary circumstance which exempts the air carrier from the obligation to pay compensation to passengers where the bus arrives at the final destination much later than its scheduled or expected arrival time?

---

(1)  Regulation (EC) No 261/2004 of the European Parliament and of the Council of 11 February 2004 establishing common rules on compensation and assistance to passengers in the event of denied boarding and of cancellation or long delay of flights, and repealing Regulation (EEC) No 295/91 (OJ 2004 L 46, p. 1).

---
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
BALANCE SHEET OF SEPTEMBER 30, 1996 AND STATEMENT OF OPERATIONS FOR THE YEAR
THEN ENDED AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<RESTATED> 
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-1996
<PERIOD-START>                             OCT-01-1995
<PERIOD-END>                               SEP-30-1996
<CASH>                                         343,484
<SECURITIES>                                         0
<RECEIVABLES>                                9,683,134
<ALLOWANCES>                                   125,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                         838,554
<DEPRECIATION>                                 192,472
<TOTAL-ASSETS>                              11,684,637
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     15,000
<COMMON>                                        72,927
<OTHER-SE>                                   4,815,530
<TOTAL-LIABILITY-AND-EQUITY>                11,684,637
<SALES>                                      7,753,507
<TOTAL-REVENUES>                             8,913,603
<CGS>                                                0
<TOTAL-COSTS>                                5,433,339
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                               220,000
<INTEREST-EXPENSE>                             462,064
<INCOME-PRETAX>                              3,480,264
<INCOME-TAX>                                   914,041
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,566,223
<EPS-PRIMARY>                                   (.073)<F1>
<EPS-DILUTED>                                        0
<FN>
<F1>RESTATED FOR EARNINGS (LOSS) PER COMMON SHARE COMPUTATION
</FN>
        

</TABLE>
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8898 Introduced in House (IH)]

<DOC>

116th CONGRESS
  2d Session
                                H. R. 8898

  To require the submission of a report to the Congress on parasitic 
                     disease among poor Americans.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            December 8, 2020

   Mr. Johnson of Georgia (for himself, Mr. Grijalva, Mr. Carson of 
   Indiana, Ms. Bass, Mr. Thompson of Mississippi, Mrs. Beatty, Ms. 
Norton, Ms. Johnson of Texas, Ms. Judy Chu of California, Mr. Bishop of 
    Georgia, Mrs. Hayes, and Ms. Lee of California) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL

 
  To require the submission of a report to the Congress on parasitic 
                     disease among poor Americans.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Neglected Infections of Impoverished 
Americans Act of 2020''.

SEC. 2. REPORT TO CONGRESS ON THE CURRENT STATE OF PARASITIC DISEASES 
              THAT HAVE BEEN OVERLOOKED AMONG THE POOREST AMERICANS.

    (a) In General.--Not later than 12 months after the date of the 
enactment of this Act, the Secretary of Health and Human Services shall 
report to the Congress on the epidemiology of, impact of, and 
appropriate funding required to address neglected diseases of poverty, 
including neglected parasitic diseases such as--
            (1) Chagas disease;
            (2) cysticercosis;
            (3) toxocariasis;
            (4) toxoplasmosis;
            (5) trichomoniasis;
            (6) the soil-transmitted helminths; and
            (7) other related parasitic diseases, as designated by the 
        Secretary.
    (b) Required Information.--The report under subsection (a) should 
provide the information necessary to guide future health policy to--
            (1) accurately evaluate the current state of knowledge 
        concerning diseases described in such subsection and define 
        gaps in such knowledge; and
            (2) address the threat of such diseases.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                          18,644
<SECURITIES>                                         0
<RECEIVABLES>                                  157,040
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      12,500,237
<DEPRECIATION>                               5,661,417
<TOTAL-ASSETS>                               7,860,569
<CURRENT-LIABILITIES>                          756,165
<BONDS>                                      7,508,185
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                 (1,821,207)
<TOTAL-LIABILITY-AND-EQUITY>                 7,860,569
<SALES>                                        912,598
<TOTAL-REVENUES>                                93,720
<CGS>                                        1,327,637
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             744,055
<INCOME-PRETAX>                            (1,548,593)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,548,593)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,548,593)
<EPS-PRIMARY>                                 (137.60)
<EPS-DILUTED>                                        0
        

</TABLE>
| (logo) WELLS FARGO | **Corporate Trust Services**

  MAC R1204-010  9062 Old Annapolis Road  Columbia, MD 21045  Tel: 410 884 2000  Fax: 410 715 2380 |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------|

 

 

Re: Annual Statement ofCompliance for Wells Fargo Commercial Mortgage Securities, Inc., CommercialMortgage  Pass-Through Certificates, Series 2015-NXS1

 

Per the Pooling and ServicingAgreement dated as of April 1, 2015 (the "Agreement"), the undersigned,a duly authorized officer of Wells Fargo Bank, N.A., as CertificateAdministrator ("Wells Fargo"), hereby certifies as follows as of andfor the year ending December 31, 2016 (the "Reporting Period"):

 

(a) A review of Wells Fargo'sactivities during the Reporting Period and of its performance under theAgreement has been made under such officer's supervision; and

 

(b) To the best of suchofficer's knowledge, based on such review, Wells Fargo has fulfilled all of itsobligations under the Agreement in all material respects throughout theReporting Period.

 

 

February 27, 2017

 

 

/s/ Brian Smith

BRIAN SMITH

Vice President

 

 

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll  go far |
|------------------------|-------------------------------------|
----

| 1.   | the      Report fully complies with the requirements of Section 13(a) and 15(d) of      the Securities Exchange Act of 1934, as amended,  and |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | the      information contained in the Report fairly presents, in all material      respects, the Company’s financial condition and results of operations as      of the dates and for the periods presented in the financial statements      included in the Report. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| /s/Timothy      W.      Simmons                              |   | /s/Roy      G.      Lindburg                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Timothy      W. Simmons                                                                                                                                                                                       |   | Roy      G. Lindburg                                                                                                                                                                                                                                 |
| Chief      Executive Officer                                                                                                                                                                                  |   | Chief      Financial Officer                                                                                                                                                                                                                         |

----
No. 11-10412.

#### Hardy *v.*West et al.

C. A. 6th Cir. Certio-rari denied.
# C_2023252EN.01000801.xml

| 17.7.2023 | EN | Official Journal of the European Union | C 252/8 |
| --- | --- | --- | --- |

17.7.2023

EN

Official Journal of the European Union

C 252/8

---

Judgment of the Court (Tenth Chamber) of 25 May 2023 (request for a preliminary ruling from the Naczelny Sąd Administracyjny — Poland) — Dyrektor Izby Administracji Skarbowej w Warszawie v W. sp. z o.o.

(Case C-114/22, (1) Dyrektor Izby Administracji Skarbowej w Warszawie (VAT — fictitious acquisition))

(Reference for a preliminary ruling - Taxation - Value added tax (VAT) - Directive 2006/112/EC - Right to deduct VAT - Refusal - Refusal based on the invalidity of the transaction under national civil law)

(2023/C 252/07)

Language of the case: Polish

Referring court

Naczelny Sąd Administracyjny

Parties to the main proceedings

Appellant: Dyrektor Izby Administracji Skarbowej w Warszawie

Respondent: W. sp. z o.o.

Operative part of the judgment

Article 167, Article 168(a), Article 178(a) and Article 273 of Council Directive 2006/112/EC of 28 November 2006 on the common system of value added tax, as amended by Council Directive 2010/45/EU of 13 July 2010, read in the light of the principles of fiscal neutrality and proportionality, must be interpreted as precluding national legislation under which a taxable person is deprived of the right to deduct input value added tax solely because a taxable economic transaction is regarded as fictitious and invalid under the provisions of national civil law, without it being necessary to establish that the criteria for classifying, under EU law, that transaction as fictitious are met or, where that transaction has actually been carried out, that it is the result of value added tax evasion or abuse of rights.

---

(1)  OJ C 284, 25.7.2022.

---
EX-10.55





 Exhibit 10.55 

Amendment No. 4 to Scientific Advisory Board Agreement 

This Amendment No. 4, effective March 31, 2018 (“Amendment Effective Date”), is made to the Scientific Advisory Board
Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016, and Amendment No. 3
to Scientific Advisory Board Agreement, dated January 1, 2017 (“Amendment No. 3”) (and collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware
corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined has the meaning ascribed to it
in the SAB Agreement. 
 WHEREAS, Company and Advisor simultaneously with Amendment No. 3 entered into a separate AgCo
Scientific Advisory Board Agreement (the “AgCo SAB Agreement”) on January 1, 2017, and the parties have mutually agreed to terminate the AgCo SAB Agreement effective March 31, 2018; 

WHEREAS, as set forth in Amendment No. 3, termination of the AgCo SAB Agreement would trigger cessation of payments from Company
to Advisor under the SAB Agreement, and the parties desire instead to continue payments from Company to Advisor under the SAB Agreement; 

NOW, THEREFORE, in consideration of the mutual covenants and undertakings hereinafter set forth, the sufficiency of which is
acknowledged, the parties agree as follows: 
  

	 	1.	 Paragraph 4 of Amendment No. 3 is hereby deleted in its entirety as of the Amendment Effective Date set
forth above. 


  

	 	2.	 Paragraph 5 of Amendment No. 3 is hereby deleted in its entirety and replaced with the following Paragraph
4 as of the Amendment Effective Date: 


 “4. Except as set forth in Paragraphs 1, 2, and 3 above, the terms and
conditions of the SAB Agreement remain in full force and effect, and the parties hereby ratify and confirm the SAB Agreement.” 
 IN
WITNESS WHEREOF, the parties have executed this Amendment No. 4 to Scientific Advisory Board Agreement as of the Amendment Effective Date. 
  

					
	Caribou Biosciences, Inc.	 		 	Jennifer A. Doudna
			
	 /s/ Rachel E. Haurwitz
	 		 	 /s/ Jennifer A. Doudna

	Rachel E. Haurwitz	 		 	
	President & CEO
[Federal Register Volume 62, Number 45 (Friday, March 7, 1997)]
[Notices]
[Page 10521]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-5632]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE
[Order No. 875]


Grant of Authority for Subzone Status; Ohmeda Caribe Inc./Ohmeda 
Pharmaceutical Manufacturing Inc. (Pharmaceutical Products) Guayama, 
Puerto Rico

    Pursuant to its authority under the Foreign-Trade Zones Act of 
June 18, 1934, as amended (19 U.S.C. 81a-81u), the Foreign-Trade 
Zones Board (the Board) adopts the following Order:

    Whereas, by an Act of Congress approved June 18, 1934, an Act ``To 
provide for the establishment * * * of foreign-trade zones in ports of 
entry of the United States, to expedite and encourage foreign commerce, 
and for other purposes,'' as amended (19 U.S.C. 81a-81u) (the Act), the 
Foreign-Trade Zones Board (the Board) is authorized to grant to 
qualified corporations the privilege of establishing foreign-trade 
zones in or adjacent to U.S. Customs ports of entry;
    Whereas, the Board's regulations (15 CFR Part 400) provide for the 
establishment of special-purpose subzones when existing zone facilities 
cannot serve the specific use involved;
    Whereas, an application from the Commercial Farm Credit and 
Development Corporation of Puerto Rico, grantee of Foreign-Trade Zone 
61, for authority to establish special-purpose subzone status at the 
pharmaceutical manufacturing plant of Ohmeda Caribe Inc./Ohmeda 
Pharmaceutical Manufacturing Inc., in Guayama, Puerto Rico, was filed 
by the Board on June 22, 1995, and notice inviting public comment was 
given in the Federal Register (FTZ Docket 33-95, 60 FR 34510, 7-3-95); 
and,
    Whereas, the Board adopts the findings and recommendations of the 
examiner's report, and finds that the requirements of the FTZ Act and 
Board's regulations are satisfied, and that approval of the application 
for a five-year period, subject to extension, is in the public 
interest;
    Now, therefore, the Board hereby grants authority for subzone 
status at the pharmaceutical manufacturing plant of Ohmeda Caribe Inc./
Ohmeda Pharmaceutical Manufacturing Inc., located in Guayama, Puerto 
Rico (Subzone 61H), at the location described in the application, for a 
period of 5 years from the date of this Board Order, subject to 
extension upon application, and subject to the FTZ Act and the Board's 
regulations, including Sec. 400.28.

    Signed at Washington, DC, this 25th day of February 1997.
Robert S. LaRussa,
Acting Assistant Secretary of Commerce for Import Administration, 
Alternate Chairman, Foreign-Trade Zones Board.
    Attest:
John J. Da Ponte, Jr.,
Executive Secretary.
[FR Doc. 97-5632 Filed 3-6-97; 8:45 am]
BILLING CODE 3510-DS-P
Exhibit 4.3







 


Consent of Independent Registered
Public Accounting Firm


We consent to the
reference made to our firm under the caption “Independent Registered Public Accounting Firm” in Part B of the Prospectus
and to the use of our report dated April 1, 2014, in this Registration Statement (Form S-6 No. 333-193738) of Smart Trust, Morningstar
Dividend Yield Focus Trust, Series 5.


 


/s/ Grant
Thornton LLP


Grant
Thornton LLP


Chicago, Illinois


April 1, 2014
# C_2022207EN.01001102.xml

| 23.5.2022 | EN | Official Journal of the European Union | C 207/11 |
| --- | --- | --- | --- |

23.5.2022

EN

Official Journal of the European Union

C 207/11

---

Request for a preliminary ruling from the Nejvyšší soud České republiky (Czech Republic) lodged on 28 January 2022 — YQ v Ředitelství silnic a dálnic ČR

(Case C-57/22)

(2022/C 207/16)

Language of the case: Czech

Referring court

Nejvyšší soud České republiky

Parties to the main proceedings

Applicant: YQ

Defendant: Ředitelství silnic a dálnic ČR

Question referred

Must Article 7(1) of Directive 2003/88/EC (1) of the European Parliament and of the Council of 4 November 2003 concerning certain aspects of the organisation of working time be interpreted as precluding national case-law by virtue of which a worker who was unlawfully dismissed then reinstated in his or her employment, in accordance with national law, following the annulment of the dismissal by a decision of a court, is not entitled to paid annual leave for the period between the date of the dismissal and that of the reinstatement in his or her employment on the ground that, during that period, that worker did not actually carry out work for the employer, also in cases when, according to national legislation, the worker who has been unlawfully dismissed and who has without undue delay informed his or her employer in writing that he or she insists on being employed, is entitled to wage or salary compensation in the amount of average earnings from the date when he or she informed the employer that he or she insists on the continuation of his or her employment until such time as the employer allows him or her to carry on in his or her work or his or her employment relationship is validly terminated?

---

(1)  OJ 2003 L 299, p. 9.

---
No. 11-10536.

#### Basat *v.*Bell, Warden.

C. A. 6th Cir. Cer-tiorari denied.